Salbutamol in treatment of heart failure.

Abstract

SUMMARY The haemodynamic effects of oral and intravenous salbutamol were investigated in 22 patients with chronic heart failure. Intravenous salbutamol (13 ,tg/min) increased cardiac index by 53 per cent from 1. There was a small rise in heart rate and a variable and not significant change in pulmonary artery enddiastolic pressure. Experiments on isolated rabbit papillary muscle showed that salbutamol, at the concentration which exists in patients, had no detectable positive inotropic effect. It is probable that the increase in cardiac output in patients is primarily the result of reduced afterload caused by vasodilatation. Salbutamol is a useful drug in the treatment of chronic heart failure.

The haemodynamic and myocardial effects of dopexamine: a new beta 2‐ adrenoceptor and dopaminergic agonist.

“…The effects of P2-adrenoceptor stimulation in humans may account for the cardiac effects of 132-adrenoceptor specific drugs such as pirbuterol or salbutamol that have also been ascribed to these agents' possible nonspecific 31-adrenoceptor activity (Sharma & Goodwin, 1978;CanepaAnson et al, 1982;Bourdillon et al, 1980).…”

“…The reported relative roles of Iland 12adrenoceptor mediated effects is variable in different species and uncertain in man (Hedberg et al, 1980;Heitz et al, 1983). The effects of P2-adrenoceptor stimulation in humans may account for the cardiac effects of 132-adrenoceptor specific drugs such as pirbuterol or salbutamol that have also been ascribed to these agents' possible nonspecific 31-adrenoceptor activity (Sharma & Goodwin, 1978;Canepa-Anson et al, 1982;Bourdillon et al, 1980).…”

Electrophysiologic Effects of Salbutamol, a β2‐Selective Agonist

“…Early studies on β 2 stimulation with oral and intravenous salbutamol in patients with chronic or acute heart failure showed significant hemodynamic changes with a decrease in systemic vascular resistance and increases in cardiac output, ejection fraction, and heart rate. These cardiovascular effects were explained as resulting from reduced afterload caused by vasodilation, which was considered to be the primary effect 3–5 …”

The effective plasma concentrations of sulmazol (AR‐L 115 BS) on haemodynamics in chronic heart failure.

“…Oral vasodilators (Hindman et al, 1980;Kirkin & Pitt, 1981;Kuck et al, 1980) such as hydralazine and prazosin are useful in this setting, however many cases of tachyphylaxis (Desch et al, 1979) have been reported and they are contra-indicated in hypotensive patients. Oral ,8-adrenoceptor agonists (Bourdillon et al, 1980;Kirkin & Pitt, 1981) such as prenalterol, pirbuterol and salbutamol may also be effective but they may increase heart rate and induce ventricular arrhythmias. Sulmazol is a new drug suitable for oral treatment, which combines inotropic and vasodilating properties (Dammgen et al, 1981;Hauf et al, 1981;Pouleur et al, 1982).…”